US equities |
MU $1,088.00 ▲+4.06% NVDA $237.47 ▼-0.74% SNDK $1,692.42 ▲+1.92% SPCX $167.60 ▼-2.51% AMD $645.86 ▼-0.55% AAPL $336.67 ▲+0.91% TSLA $377.81 ▼-0.75% META $721.31 ▼-2.38%
FinancialContent

Articles published by Editas Medicine, Inc.

< Previous 1 2 3 Next >
News headline image
Editas Medicine Reports Inducement Grants to New Chief Medical Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Second Quarter 2026 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Strengthens Board of Directors with Appointment of Patrick T. Ellinor, M.D., Ph.D.
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Updated Presentation Time for Upcoming Investor Conference
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Pricing of Up to $319.4 Million Public Offering
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Proposed Public Offering
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Presents EDIT-401 Preclinical Data Demonstrating Robust Reductions in LDL-C, Lp(a), and ApoB in Non-Human Primates at the 94th European Atherosclerosis Society Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces First Quarter 2026 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine to Present New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at Upcoming Scientific Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces U.S. Patent and Trademark Office Reaffirms its Prior Decision in Favor of the Broad Institute in CRISPR/Cas9 Interference
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine to Host Webinar Announcing Lead In Vivo Development Candidate
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine to Participate in Upcoming Investor Conferences
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces Second Quarter 2025 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Reports New In Vivo Data Highlighting the Potential of Editas’ Gene Upregulation Strategy in HSCs at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces First Quarter 2025 Results and Business Updates
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine Announces U.S. Court of Appeals for the Federal Circuit Remands CRISPR Patent Interference to Patent Trial and Appeal Board
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
News headline image
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
From Editas Medicine, Inc.
Via GlobeNewswire
Tickers EDIT
< Previous 1 2 3 Next >